Kinetics of C5a release in cardiac lymph of dogs experiencing coronary artery ischemia-reperfusion injury.
暂无分享,去创建一个
W. Dreyer | M. Entman | C. Smith | R. Rossen | L. Michael | D. Anderson | T. Nguyen | T. Nguyen | C. Smith
[1] W. Dreyer,et al. Neutrophil Accumulation in Ischemic Canine Myocardium: Insights Into Time Course, Distribution, and Mechanism of Localization During Early Reperfusion , 1991, Circulation.
[2] P. Ward,et al. THE PHLOGISTIC ROLE OF C3 LEUKOTACTIC FRAGMENTS IN MYOCARDIAL INFARCTS OF RATS , 1971, The Journal of experimental medicine.
[3] A. M. Lefer,et al. Thromboxane Is Produced in Response to Intracoronary Infusions of Complement C5a in Pigs Cyclooxygenase Blockade Does Not Reduce the Myocardial Ischemia and Leukocyte Accumulation , 1989, Circulation research.
[4] Giclas Pc,et al. In vitro activation of complement by isolated human heart subcellular membranes. , 1979 .
[5] J. Salmon,et al. Leukocyte-derived metabolites of arachidonic acid in ischemia-induced myocardial injury. , 1987, Federation proceedings.
[6] C. Gerard,et al. Anaphylatoxin from the fifth component of porcine complement. Purification and partial chemical characterization. , 1979, The Journal of biological chemistry.
[7] R. O'rourke,et al. Consumption of classical complement components by heart subcellular membranes in vitro and in patients after acute myocardial infarction. , 1975, The Journal of clinical investigation.
[8] C. Smith,et al. The role of leukocytes in ischemic damage, reperfusion injury and repair of the myocardium , 1990 .
[9] S. Calvano,et al. Myocardial reperfusion injury. Platelet-activating factor stimulates polymorphonuclear leukocyte hydrogen peroxide production during myocardial reperfusion. , 1991, The Journal of thoracic and cardiovascular surgery.
[10] B. Tack,et al. Fifth component of human complement: purification from plasma and polypeptide chain structure. , 1979, Biochemistry.
[11] A. M. Lefer,et al. Role of platelet activating factor in propagation of cardiac damage during myocardial ischemia. , 1988, The Journal of pharmacology and experimental therapeutics.
[12] M. Entman,et al. Selective Accumulation of the First Component of Complement and Leukocytes in Ischemic Canine Heart Muscle: A Possible Initiator of an Extra Myocardial Mechanism of Ischemic Injury , 1985, Circulation research.
[13] L. McManus,et al. Complement and neutrophil activation in the pathogenesis of ischemic myocardial injury. , 1988, Circulation.
[14] M. Schork,et al. The Effect of Ibuprofen on Accumulation of Indium‐111‐labeled Platelets and Leukocytes in Experimental Myocardial Infarction , 1982, Circulation.
[15] T. Plummer,et al. A potent mercapto bi-product analogue inhibitor for human carboxypeptidase N. , 1981, Biochemical and biophysical research communications.
[16] C. Gerard,et al. Amino acid sequence of the anaphylatoxin from the fifth component of porcine complement. , 1980, The Journal of biological chemistry.
[17] M. Olson,et al. Characterization of the binding of purified human C1q to heart mitochondrial membranes. , 1981, The Journal of biological chemistry.
[18] R. Engler,et al. Thromboxane A2 and peptidoleukotrienes contribute to the myocardial ischemia and contractile dysfunction in response to intracoronary infusion of complement C5a in pigs. , 1990, Circulation research.
[19] M. Chiariello,et al. Reduction by cobra venom factor of myocardial necrosis after coronary artery occlusion. , 1978, The Journal of clinical investigation.
[20] M. Entman,et al. Creatine kinase and phosphorylase in cardiac lymph: coronary occlusion and reperfusion. , 1985, The American journal of physiology.
[21] J. Longhurst,et al. Role of thromboxane A2 in the cardiovascular response to intracoronary C5a. , 1990, Circulation research.
[22] M. Nonaka,et al. The complement system in rainbow trout (Salmo gairdneri). II. Purification and characterization of the fifth component (C5). , 1981, Journal of immunology.
[23] T. Kinoshita,et al. Fifth component of guinea pig complement: purification and characterization. , 1981, Journal of immunology.
[24] H. Tai,et al. Hypoxia provokes leukotriene-dependent neutrophil sequestration in perfused rabbit hearts. , 1987, The Journal of pharmacology and experimental therapeutics.
[25] M. Entman,et al. Myocardial Ischemia: Platelet and Thromboxane Concentrations in Cardiac Lymph and the Effects of Ibuprofen and Prostacyclin , 1986, Circulation research.
[26] A. Huber,et al. Regulation of transendothelial neutrophil migration by endogenous interleukin-8. , 1991, Science.
[27] C. Smith,et al. Motility and adhesiveness in human neutrophils. Effects of chemotactic factors. , 1979, The Journal of clinical investigation.
[28] G. Carter,et al. Chemical synthesis of a gene encoding the human complement fragment C5a and its expression in Escherichia coli. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[29] R. O'rourke,et al. Antibody-independent activation of human C1 after interaction with heart subcellular membranes. , 1973, Journal of immunology.
[30] M. Entman,et al. Molecular Basis of Complement Activation in Ischemic Myocardium: Identification of Specific Molecules of Mitochondrial Origin That Bind Human Clq and Fix Complement , 1989, Circulation research.
[31] J. Mehta,et al. Neutrophils as potential participants in acute myocardial ischemia: relevance to reperfusion. , 1988, Journal of the American College of Cardiology.
[32] M. Olson,et al. In vitro activation of complement by isolated human heart subcellular membranes. , 1979, Journal of immunology.
[33] M. Entman,et al. Mechanism of Complement Activation After Coronary Artery Occlusion: Evidence That Myocardial Ischemia in Dogs Causes Release of Constituents of Myocardial Subcellular Origin That Complex With Human C1q In Vivo , 1988, Circulation research.
[34] G. R. Carson,et al. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. , 1990, Science.